Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
touchCONGRESS
Our faculty interpret key data from the congress, complimented by an expert panel discussing what has been presented.
Close
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
Learning Objectives
After watching this activity, participants should be better able to:
- Evaluate the latest evidence for current BCMA-targeting therapies for patients with multiple myeloma
- Review emerging BCMA-targeting therapies being evaluated in clinical trials for patients with multiple myeloma
- Discuss the impact of the latest data for current and emerging BCMA-targeting agents on the future management of patients with multiple myeloma
Overview
In this activity, an expert in multiple myeloma reviews key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Two further experts then join to discuss how these data may apply in clinical practice.
This activity was filmed following the 10th COMy World Congress (Paris, France and online; 23–26 May 2024) and 29th EHA2024 Hybrid Congress (Madrid, Spain; 13–16 June).
This activity is provided by touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of haematologists, including haemato-oncologists, and oncologists involved in the management of multiple myeloma.
EBAC® Accreditation
touchIME is an EBAC® accredited provider since 2023.
This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for upto 1.25 hours of effective education time. Each participant should claim only time that has been spent in the educational activity.
The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Faculty
Prof. María-Victoria Mateos discloses: Advisory board, panel and/or speaker bureau fees from AbbVie, Amgen, Celgene, GSK, Janssen, Kite, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Stemline and Takeda.
Dr Rakesh Popat discloses: Advisory board or panel fees from GSK, Johnson & Johnson, Roche and Sanofi. Consultant fees from GSK and Regeneron. Grants/research support from GSK and Pfizer. Other financial or material support (royalties, patent, etc) from AbbVie, BMS, GSK, Johnson & Johnson and Pfizer. Speaker Bureau fees from Pfizer.
Prof. Evangelos Terpos discloses: Employee or independent contractor fees from Amgen, Antengene, AstraZeneca, BMS, GSK, Janssen, Pfizer, Sanofi, Swixx Biopharma and Takeda. Advisory board or panel fees from BMS, GSK, Janssen, Pfizer and Swixx Biopharma. Grants/research support from GSK, Janssen, Sanofi and Takeda.
Touch Medical Contributors
Hannah Fisher and Christina Mackins-Crabtree have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.
Date of original release: 10 October 2024. Date credits expire: 10 October 2025.
Time to Complete: 55 minutes
If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org
To obtain the credit(s) from this activity, please complete this post-activity test.
Claim CreditCourse Modules
You may also be interested in...
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 10 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out